Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jan;98(2):e13923.
doi: 10.1097/MD.0000000000013923.

Clinicopathologic and prognostic significance of tumor-infiltrating CD8+ T cells in patients with hepatocellular carcinoma: A meta-analysis

Affiliations
Review

Clinicopathologic and prognostic significance of tumor-infiltrating CD8+ T cells in patients with hepatocellular carcinoma: A meta-analysis

Xuezhong Xu et al. Medicine (Baltimore). 2019 Jan.

Abstract

Background: In patients with hepatocellular carcinoma (HCC), the clinicopathologic and prognostic roles of tumor-infiltrating CD8+ T cells for survival are still controversial. A meta-analysis was performed to resolve this issue.

Methods: We identified studies from PubMed, Embase, and the Cochrane Library to evaluate the clinicopathologic and prognostic value of tumor-infiltrating CD8+ T cells in patients with HCC. A meta-analysis was conducted to estimate clinicopathologic characteristics, overall survival (OS), and disease-free survival. The hazard ratio (HR) and 95% confidence interval (CI) were calculated employing fixed-effect or random-effect models depending on the heterogeneity of the included trials.

Results: A total of 3509 patients from 21 observational studies were enrolled. The meta-analysis revealed that high levels of intratumoral CD8+ tumor-infiltrating lymphocytes (TILs) were associated with better OS (OS; HR = 0.676, P = .001) and disease-free survival (disease-free survival [DFS]; HR = 0.712, P = .002). The pooled analysis also demonstrated high density of infiltration of CD8+ TILs in margin of tumor (MT) was statistically significant associated with better OS (HR = 0.577; P <.001). Moreover, the patients with low CD8+ TILs infiltration had negative HBSAg (OR = 1.67, P = .02), large tumor size (OR = 1.74, P <.01), and later TNM stage (OR = 1.70, P <.01).

Conclusions: Our findings suggested that low levels of CD8+ TILs predict large tumor size, later TNM stage and might be a promising prognostic factor of HCC especially for Asian patients. High-quality randomized controlled trials are needed to determine if CD8+ TILs could serve as targets for immunotherapy in hepatocellular carcinoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Flow diagram of study selection.
Figure 2
Figure 2
Forest plots of studies evaluating the association between CD8+ lymphocytes and OS of HCC patients. OS = overall survival, HCC = hepatocellular carcinoma.
Figure 3
Figure 3
Forest plots of studies evaluating the association between CD8+ lymphocytes and DFS of HCC patients. DFS = disease free survival, HCC = hepatocellular carcinoma.
Figure 4
Figure 4
Cumulative meta-analysis of the association between CD8+ TILs and prognosis. (A) Intratumoral CD8+ lymphocytes and OS; (B) Intratumoral CD8+ lymphocytes and DFS. DFS = disease free survival, OS = overall survival, TILs = tumor-infiltrating lymphocytes.
Figure 5
Figure 5
Sensitivity analyses of the association between CD8+ TILs and prognosis. (A) Sensitivity analysis of the association between CD8+ lymphocytes in IT and OS; (B) Sensitivity analysis of the association between CD8+ lymphocytes in IT and DFS. DFS = disease free survival, IT = intratumor, OS = overall survival, TILs = tumor-infiltrating lymphocytes.
Figure 6
Figure 6
Egger's tests of the association between CD8+ TILs and prognosis. (A) Egger's tests of the association between CD8+ lymphocytes in IT and OS; (B) Egger's tests of the association between CD8+ lymphocytes in IT and DFS. DFS = disease free survival, IT = intratumor, OS = overall survival, TILs = tumor-infiltrating lymphocytes.

Similar articles

Cited by

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA: Cancer J Clin 2015;65:5–29. - PubMed
    1. Rasool M, Rashid S, Arooj M, et al. New possibilities in hepatocellular carcinoma treatment. Anticancer Res 2014;34:1563–71. - PubMed
    1. Hiraoka N. Tumor-infiltrating lymphocytes and hepatocellular carcinoma: molecular biology. Int J Clin Oncol 2010;15:544–51. - PubMed
    1. Fu J, Zhang Z, Zhou L, et al. Impairment of CD4+ cytotoxic T cells predicts poor survival and high recurrence rates in patients with hepatocellular carcinoma. Hepatology 2013;58:139–49. - PubMed
    1. Wada Y, Nakashima O, Kutami R, et al. Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. Hepatology 1998;27:407–14. - PubMed

MeSH terms